If one just considers the capoxone sales of $2 Billion in US and that Feb 2011 (just 5 months away), MNTA may enter that arena as well (is that true?).......
Doesn't it seem that the worry over multiple generics in Lovenox is overdone if capaxone is right on the heels of Lovenox?
It would seem that at 50% of capaxone market and 20% drug discount, there is a potential revenue of $800 million to their partnership.......less expenses would seem to be a pretty nice earnings addition. These earnings may be greater than Lovenox regardless?
News 
Market Data 
Discover 
AI
